Presenting this month #MarchMadness our own @anamomerMD on outcomes of postoperative endoscopic recurrence in Crohn disease published recently in @AmJGastro of @AmCollegeGastro
Watch video abstract 📽️👇
Introduction: Early ileocolonoscopy within the first year after surgery is the gold standard to evaluate recurrence after ileocolonic resection for Crohn's disease (CD)
The aim of the study was to evaluate the association between the presence and severity of anastomotic and ileal lesions at early postoperative ileocolonoscopy and long-term outcomes
Method: The REMIND group ( France) conducted a prospective multicenter study. Patients operated for ileal or ileocolonic CD were included. An ileocolonoscopy was performed 6 months after surgery
Method: An endoscopic score describing separately the anastomotic and ileal lesions was built. Clinical relapse was defined by the CD-related symptoms, confirmed by imaging, endoscopy or therapeutic intensification; CD-related complications; or subsequent surgery
Results: Median clinical recurrence-free survival was 47.6 months. Clinical recurrence-free survival was significantly shorter in patients with ileal lesions at early postoperative endoscopy whatever their severity was (I(1) or I(2,3,4))
Results: Patients with exclusively ileal lesions (A(0)I(1,2,3,4)) had poorer clinical long-term outcomes than patients with exclusively anastomotic lesions (A(1,2,3)I(0)) (P = 0.009).
Results: Severe anastomotic lesions (more than semi circumferential ulcers here graded A(2) or A(3)) were associated with significantly more occlusive complications and a trend toward a higher clinical recurrence
Conclusion: A score describing separately the anastomotic and ileal lesions might be more appropriate to define postoperative endoscopic recurrence.
Conclusion: The data suggest that patients with ileal lesions, including mild ones (I(1)), could beneficiate from treatment step-up to improve long-term outcomes.
Limitations: The major limitation of our study is the absence of endoscopic central reading, which could have led to misclassifications of the endoscopic lesions.
These results suggest that mild lesions (I(1)) should be taken into account for treatment escalation or optimization. The REMIND score proposed here, describing separately anastomotic and ileal lesions, might be more appropriate to predict the postoperative outcomes.
1. Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience.
Viewpoint on how operationally to manage IBD patients and ensure quality of care in the current pandemic era.#ibdclub academic.oup.com/ecco-jcc/advan…
2-Management of IBD during the COVID-19 outbreak: resetting clinical priorities. Changes & clinical issues IBD specialists could face during SARSCoV2 pan, highlighting potential rearrangements of care &resetting of clinical priorities @NatRevGastroHep nature.com/articles/s4157…
Here is the latest updates from International Organization for the Study of Inflammatory Bowel Diseases released March 26, 2020. Salient features summarized below . For full information: ioibd.org/ioibd-update-o…
Important to know: These statements represent summation of expert opinion and should be interpreted in context of the individual patient and the managing healthcare provider who knows her or him. These are not guidelines and may be updated as knowledge and the situation evolve.
1- It is uncertain if active inflammation from IBD increases the risk of getting SARS-CoV-2.
2-It is uncertain if patients with IBD who develop COVID-19 have a higher mortality compared to patients without IBD.